Additional Info
Properties
- PT-141 Chemical Formula: C50H68N14O10
- PT-141 Molecular Weight: 1025.2 g/mol
- PT-141 Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH
- Total Amount of the Active Ingredient: 10mg (1 vial)
- Shelf Life: 36 months
Shipping
- USA
- Canada
- Shipping Disclaimer: If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Disclaimer
The information above does not substitute medical advice, diagnosis, or treatment. If you have questions about a medical condition, consult your physician or qualified healthcare provider promptly. Never delay seeking medical advice based on information you have read or seen. We assume no liability for the use of our research compounds and products. These items are sold exclusively for research purposes. We do not endorse personal use.
Additional Label & Product Information
Essential warning:
The chemicals contained are for research or laboratory use only. Not approved by the FDA for human consumption.
Using instructions:
- Avoid skin and eye contact. Rinse immediately with plenty of water if contact occurs.
- Seek medical advice if feeling unwell or in case of accidental ingestion.
- Store the lyophilized (freeze-dried) peptide at room temperature upon receipt. Avoid repeated freeze-thaw cycles for peptide stability.
Product Disclaimer:
This product is not intended to diagnose, treat, cure, or prevent any disease. Apply only as directed by specific research or laboratory protocols.
Resources
- Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M., & Molinoff, P. B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research, 16(2), 135-142. https://doi.org/10.1038/sj.ijir.3901200
- Rössler, A. S., Pfaus, J. G., Kia, H. K., Bernabé, J., Alexandre, L., & Giuliano, F. (2006). The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacology Biochemistry and Behavior, 85(3), 514-521. https://doi.org/10.1016/j.pbb.2006.09.023
- Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., … Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: A randomized, placebo-controlled dose-finding trial. Women’s Health (London, England), 12(3), 325-337. https://doi.org/10.2217/whe-2016-0018
- Miller, M. K., Smith, J. R., Norman, J. J., & Clayton, A. H. (2018). Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opinion on Emerging Drugs, 23(3), 223-230. https://doi.org/10.1080/14728214.2018.1527901
- Ji, H. X., Zou, Y. L., Duan, J. J., Jia, Z. R., Li, X. J., Wang, Z., … Yang, Y. (2013). The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization. PLoS One, 8(2), e56004. https://doi.org/10.1371/journal.pone.0056004
- Maresca, V., Flori, E., & Picardo, M. (2015). Skin phototype: A new perspective. Pigment Cell & Melanoma Research, 28(4), 378-389. https://doi.org/10.1111/pcmr.12365
- Feller, L., Khammissa, R. A. G., Kramer, B., Altini, M., & Lemmer, J. (2016). Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head & Face Medicine, 12, 11. https://doi.org/10.1186/s13005-016-0106-0
Reviews
There are no reviews yet.